Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michele Ghidini

Showing results (161-170 of 206) with videos related to

Pageof 21
Sort By:
ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Characterisation of the immune-related transcriptome in resected biliary tract cancersMichele Ghidini, Luciano Cascione, Pietro Carotenuto, et al.
Oncotarget|January 18, 2018
First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II studyGianluca Tomasello, Nicola Valeri, Michele Ghidini, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2019
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre studyAlessandro Parisi, Alessio Cortellini, Michela Roberto, et al.
Journal of Clinical Medicine|September 23, 2022
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGASTMassimiliano Salati, Nicola De Ruvo, Mariano Cesare Giglio, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
The Lancet. Oncology|October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trialKohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
Cancers|November 26, 2022
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort StudyStefano Granieri, Christian Cotsoglou, Alessandro Bonomi, et al.
Pageof 21

Showing results (161-170 of 206) with videos related to

Sort By:
Pageof 21
ESMO Open|December 7, 2017
Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical studyChiara Cremolini, Filippo Pietrantonio, Gianluca Tomasello, et al.
JAMA Oncology|October 11, 2019
Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy: Subgroup Analyses of a Randomized Clinical TrialDavid H Ilson, Josep Tabernero, Aliaksandr Prokharau, et al.
European Journal of Cancer (Oxford, England : 1990)|October 9, 2017
Characterisation of the immune-related transcriptome in resected biliary tract cancersMichele Ghidini, Luciano Cascione, Pietro Carotenuto, et al.
Oncotarget|January 18, 2018
First-line dose-dense chemotherapy with docetaxel, cisplatin, folinic acid and 5-fluorouracil (DCF) plus panitumumab in patients with locally advanced or metastatic cancer of the stomach or gastroesophageal junction: final results and biomarker analysis from an Italian oncology group for clinical research (GOIRC) phase II studyGianluca Tomasello, Nicola Valeri, Michele Ghidini, et al.
Journal of Cancer Research and Clinical Oncology|July 8, 2019
Weight loss and body mass index in advanced gastric cancer patients treated with second-line ramucirumab: a real-life multicentre studyAlessandro Parisi, Alessio Cortellini, Michela Roberto, et al.
Journal of Clinical Medicine|September 23, 2022
Development and Multicenter Validation of a Novel Immune-Inflammation-Based Nomogram to Predict Survival in Western Resectable Gastric and Gastroesophageal Junction Adenocarcinoma (GEA): The NOMOGASTMassimiliano Salati, Nicola De Ruvo, Mariano Cesare Giglio, et al.
Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association|March 5, 2020
Health-related quality of life associated with trifluridine/tipiracil in heavily pretreated metastatic gastric cancer: results from TAGSJosep Tabernero, Maria Alsina, Kohei Shitara, et al.
Vaccines|May 2, 2020
The Agnostic Role of Site of Metastasis in Predicting Outcomes in Cancer Patients Treated with ImmunotherapyAndrea Botticelli, Alessio Cirillo, Simone Scagnoli, et al.
The Lancet. Oncology|October 26, 2018
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trialKohei Shitara, Toshihiko Doi, Mikhail Dvorkin, et al.
Cancers|November 26, 2022
Conversion Strategy in Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer Patients with Unresectable Liver-Limited Disease: A Multicenter Cohort StudyStefano Granieri, Christian Cotsoglou, Alessandro Bonomi, et al.
Pageof 21